vs

Side-by-side financial comparison of CITIZENS FINANCIAL SERVICES INC (CZFS) and EXAGEN INC. (XGN). Click either name above to swap in a different company.

CITIZENS FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($29.6M vs $16.6M, roughly 1.8× EXAGEN INC.). CITIZENS FINANCIAL SERVICES INC runs the higher net margin — 35.4% vs -28.1%, a 63.5% gap on every dollar of revenue. On growth, EXAGEN INC. posted the faster year-over-year revenue change (21.8% vs 13.0%). CITIZENS FINANCIAL SERVICES INC produced more free cash flow last quarter ($35.2M vs $-3.1M). Over the past eight quarters, EXAGEN INC.'s revenue compounded faster (7.4% CAGR vs 6.9%).

Citizens Financial Group, Inc. is an American bank holding company, headquartered in Providence, Rhode Island. The company owns the bank Citizens Bank, N.A., which operates in the U.S. states of Connecticut, Delaware, Florida, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Vermont, and Virginia, as well as Washington, DC.

Exagen Inc. is a clinical diagnostics company specializing in developing, manufacturing, and commercializing proprietary testing solutions for autoimmune, rheumatic, and related chronic diseases. It mainly operates in the U.S. market, serving healthcare providers and patients to support accurate disease diagnosis and treatment monitoring.

CZFS vs XGN — Head-to-Head

Bigger by revenue
CZFS
CZFS
1.8× larger
CZFS
$29.6M
$16.6M
XGN
Growing faster (revenue YoY)
XGN
XGN
+8.8% gap
XGN
21.8%
13.0%
CZFS
Higher net margin
CZFS
CZFS
63.5% more per $
CZFS
35.4%
-28.1%
XGN
More free cash flow
CZFS
CZFS
$38.3M more FCF
CZFS
$35.2M
$-3.1M
XGN
Faster 2-yr revenue CAGR
XGN
XGN
Annualised
XGN
7.4%
6.9%
CZFS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CZFS
CZFS
XGN
XGN
Revenue
$29.6M
$16.6M
Net Profit
$10.5M
$-4.7M
Gross Margin
55.4%
Operating Margin
44.2%
-29.9%
Net Margin
35.4%
-28.1%
Revenue YoY
13.0%
21.8%
Net Profit YoY
31.3%
-24.2%
EPS (diluted)
$2.17
$-0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZFS
CZFS
XGN
XGN
Q4 25
$29.6M
$16.6M
Q3 25
$29.0M
$17.2M
Q2 25
$27.3M
$17.2M
Q1 25
$26.4M
$15.5M
Q4 24
$26.2M
$13.7M
Q3 24
$25.1M
$12.5M
Q2 24
$24.6M
$15.1M
Q1 24
$25.9M
$14.4M
Net Profit
CZFS
CZFS
XGN
XGN
Q4 25
$10.5M
$-4.7M
Q3 25
$10.0M
$-7.1M
Q2 25
$8.5M
$-4.4M
Q1 25
$7.6M
$-3.8M
Q4 24
$8.0M
$-3.8M
Q3 24
$7.5M
$-5.0M
Q2 24
$5.3M
$-3.0M
Q1 24
$7.0M
$-3.4M
Gross Margin
CZFS
CZFS
XGN
XGN
Q4 25
55.4%
Q3 25
58.4%
Q2 25
60.4%
Q1 25
58.9%
Q4 24
62.1%
Q3 24
55.8%
Q2 24
60.1%
Q1 24
59.6%
Operating Margin
CZFS
CZFS
XGN
XGN
Q4 25
44.2%
-29.9%
Q3 25
42.6%
-18.0%
Q2 25
38.1%
-15.3%
Q1 25
35.5%
-21.7%
Q4 24
37.2%
-24.8%
Q3 24
36.9%
-37.3%
Q2 24
25.9%
-17.2%
Q1 24
32.8%
-20.8%
Net Margin
CZFS
CZFS
XGN
XGN
Q4 25
35.4%
-28.1%
Q3 25
34.5%
-41.1%
Q2 25
31.0%
-25.8%
Q1 25
28.8%
-24.2%
Q4 24
30.5%
-27.5%
Q3 24
30.0%
-40.2%
Q2 24
21.4%
-19.7%
Q1 24
27.1%
-23.3%
EPS (diluted)
CZFS
CZFS
XGN
XGN
Q4 25
$2.17
$-0.21
Q3 25
$2.09
$-0.31
Q2 25
$1.76
$-0.21
Q1 25
$1.60
$-0.20
Q4 24
$1.64
$-0.20
Q3 24
$1.57
$-0.28
Q2 24
$1.10
$-0.16
Q1 24
$1.48
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZFS
CZFS
XGN
XGN
Cash + ST InvestmentsLiquidity on hand
$34.3M
$32.2M
Total DebtLower is stronger
$22.9M
Stockholders' EquityBook value
$338.1M
$17.4M
Total Assets
$3.1B
$58.0M
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZFS
CZFS
XGN
XGN
Q4 25
$34.3M
$32.2M
Q3 25
$31.1M
$35.7M
Q2 25
$49.5M
$30.0M
Q1 25
$36.8M
$11.2M
Q4 24
$42.2M
$22.0M
Q3 24
$36.8M
$22.0M
Q2 24
$38.4M
$24.5M
Q1 24
$29.6M
$27.3M
Total Debt
CZFS
CZFS
XGN
XGN
Q4 25
$22.9M
Q3 25
$22.9M
Q2 25
$23.0M
Q1 25
$20.9M
Q4 24
$20.2M
Q3 24
$20.3M
Q2 24
$20.3M
Q1 24
$19.5M
Stockholders' Equity
CZFS
CZFS
XGN
XGN
Q4 25
$338.1M
$17.4M
Q3 25
$327.7M
$18.1M
Q2 25
$313.7M
$21.0M
Q1 25
$308.3M
$6.4M
Q4 24
$299.7M
$9.5M
Q3 24
$298.7M
$12.9M
Q2 24
$286.5M
$17.6M
Q1 24
$282.7M
$20.0M
Total Assets
CZFS
CZFS
XGN
XGN
Q4 25
$3.1B
$58.0M
Q3 25
$3.1B
$62.8M
Q2 25
$3.0B
$58.8M
Q1 25
$3.0B
$40.3M
Q4 24
$3.0B
$44.7M
Q3 24
$3.0B
$43.6M
Q2 24
$2.9B
$49.3M
Q1 24
$2.9B
$50.8M
Debt / Equity
CZFS
CZFS
XGN
XGN
Q4 25
1.31×
Q3 25
1.26×
Q2 25
1.09×
Q1 25
3.27×
Q4 24
2.12×
Q3 24
1.57×
Q2 24
1.15×
Q1 24
0.98×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZFS
CZFS
XGN
XGN
Operating Cash FlowLast quarter
$36.5M
$-3.0M
Free Cash FlowOCF − Capex
$35.2M
$-3.1M
FCF MarginFCF / Revenue
119.0%
-18.4%
Capex IntensityCapex / Revenue
4.4%
0.3%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$53.8M
$-14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZFS
CZFS
XGN
XGN
Q4 25
$36.5M
$-3.0M
Q3 25
$2.9M
$2.9M
Q2 25
$6.0M
$-2.9M
Q1 25
$10.9M
$-10.7M
Q4 24
$33.2M
$363.0K
Q3 24
$6.2M
$-2.2M
Q2 24
$3.0M
$-2.4M
Q1 24
$13.5M
$-9.0M
Free Cash Flow
CZFS
CZFS
XGN
XGN
Q4 25
$35.2M
$-3.1M
Q3 25
$2.7M
$2.7M
Q2 25
$5.5M
$-3.1M
Q1 25
$10.4M
$-10.8M
Q4 24
$31.9M
$217.0K
Q3 24
$5.6M
$-2.3M
Q2 24
$2.9M
$-2.6M
Q1 24
$13.4M
$-9.1M
FCF Margin
CZFS
CZFS
XGN
XGN
Q4 25
119.0%
-18.4%
Q3 25
9.4%
15.5%
Q2 25
20.1%
-18.0%
Q1 25
39.2%
-69.6%
Q4 24
121.6%
1.6%
Q3 24
22.3%
-18.6%
Q2 24
11.8%
-17.0%
Q1 24
51.5%
-63.3%
Capex Intensity
CZFS
CZFS
XGN
XGN
Q4 25
4.4%
0.3%
Q3 25
0.5%
1.6%
Q2 25
1.8%
1.2%
Q1 25
2.2%
0.7%
Q4 24
5.0%
1.1%
Q3 24
2.5%
1.2%
Q2 24
0.5%
0.9%
Q1 24
0.4%
0.6%
Cash Conversion
CZFS
CZFS
XGN
XGN
Q4 25
3.49×
Q3 25
0.29×
Q2 25
0.71×
Q1 25
1.44×
Q4 24
4.16×
Q3 24
0.83×
Q2 24
0.57×
Q1 24
1.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CZFS
CZFS

Segment breakdown not available.

XGN
XGN

Commercial$9.3M56%
Government1$4.3M26%
Client Direct Bill$2.9M18%

Related Comparisons